Search

The aim of the study is to evaluate the efficacy of the combination of Raman spectroscopy with feature engineering and machine learning algorithms for detecting glioma patients. In this study, we used Raman spectroscopy technology to collect serum spectra of glioma patients and healthy people and used feature engineering-based classification models for prediction. First, to reduce the dimensionality of the data, we used two feature extraction algorithms which are partial least squares (PLS) and principal component analysis (PCA). Then, the principal components were selected using the feature selection methods of four correlation indexes, namely, Relief-F (RF), the Pearson correlation coefficient (PCC), the F-score (FS) and term variance (TV). Finally, back-propagation neural network (BP), linear discriminant analysis (LDA) and support vector machine (SVM) classification models were established. To improve the reliability of the model, we used a fivefold cross validation to measure the prediction performance between different models. In this experiment, 33 classification models were established. Integrating 4 classification criteria, PLS-Relief-F-BP, PLS-F-Score-BP, PLS-LDA and PLS-Relief-F-SVM had better effects, and their accuracy rates reached 97.58%, 96.33%, 97.87% and 96.19%, respectively. The experimental results show that feature engineering can select more representative features, reduce computational time complexity and simplify the model. The classification model established in this experiment can not only increase the robustness of the model and shorten the discrimination time but also realize the rapid, stable and accurate diagnosis of glioma patients, which has high clinical application value. [ABSTRACT FROM AUTHOR]

Researchers have established a classification model based on tear Raman spectroscopy combined with machine learning classification algorithms, which realizes rapid noninvasive classification of cerebral infarction and cerebral ischemia, which is of great significance for clinical medical diagnosis. Through spectral data analysis, it is found that there are differences in the content of tyrosine, phenylalanine, and carotenoids in the tears of patients with cerebral ischemia and patients with cerebral infarction. We try to establish a classification model for rapid noninvasive screening of cerebral infarction and cerebral ischemia through these differences. The experiment has four parts, including normalization, data enhancement, feature extraction, and data classification. The researchers combined three feature extraction methods with four machine classification models to build a total of 12 classification models. Integrating 8 classification criteria, the classification accuracy of all models is above 85%, especially PLS-PNN has achieved 100% accuracy and better running time. The experimental results show that tear Raman spectroscopy combined with machine learning classification model has a good effect on the screening of cerebral ischemia and cerebral infarction, which is conducive to the noninvasive and rapid clinical diagnosis of cerebrovascular diseases in the future. [ABSTRACT FROM AUTHOR]

This study presents a rapid method to screen hepatitis B patients using serum Raman spectroscopy combined with long short-term memory neural network (LSTM). The serum samples taken from 435 hepatitis B patients and 699 non-hepatitis B people were measured in this experiment. Specific biomolecular changes in three groups of serum samples could be seen in the tentative assignment of Raman peaks. First, principal component analysis (PCA) was used for extracting key features of spectral data, which reduces the dimension of the multidimensional spectrum. Then, LSTM is used to train the spectral data. Finally, the full connection layer completes the classification of HBV. The diagnostic accuracy of the first LSTM model is 97.32%, and the value of AUC is 0.995. The results from the study demonstrate that the combination of serum Raman spectroscopy technique and LSTM provides an effective technical approach to the screening of hepatitis B. [ABSTRACT FROM AUTHOR]